Table 1 Demographic and clinical variables
Group A (n = 12) | Group B (n = 65) | p-value | |
|---|---|---|---|
Median (Min–Max) | Median (Min–Max) | ||
Sex (Male/Female) | M 7/F 5 | M 42/F 23 | N.S. |
Age (months) | 27 (4–65) | 21 (2–9) | N.S. |
Presenting symptoms (in KD criteria) | 5 (5–6) | 5 (3–6) | N.S. |
Fever duration (days) | 7 (4–10) | 6 (4–15) | N.S. |
Duration of hospitalization (days) | 11 (7–38) | 9 (6–25) | N.S. |
CA involvement (n) | 4 | 6 | 0.001* |
Treatment | |||
Aspirin/Flurbiprofen (day of administration)† | 4 (3–8) | 5 (2–9) | N.S. |
Initial IVIG (day of administration)† | 4 (4–8) | 5 (3–8) | N.S. |
Second IVIG (n) | 6 | 14 | N.S. |
Alternative Treatments | 3rd IVIG | PE (2) Infliximab (1) Steroids (2) | |
Total IVIG dosage (g/kg) | 3 (2–6) | 2 (2–4) | 0.020** |